DOCSLIB.ORG

(SEAC) Held on 19/03/2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(SEAC) Held on 19/03/2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar Minutes of the 613th meeting of the State Level Expert Appraisal Committee (SEAC) held on 19/03/2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar. The 613th meeting of the State Level Expert Appraisal Committee (SEAC) was held on 19th March 2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar. Following members attended the meeting: 1. Dr. Dinesh Misra, Chairman, SEAC 2. Shri S. C. Srivastav, Vice Chairman, SEAC 3. Shri V. N. Patel, Member, SEAC 4. Shri. R. J. Shah, Member, SEAC 5. Shri A. K. Muley, Member, SEAC The regular agenda of Appraisal, Screening & Scoping/ ToR / EC – Reconsideration cases were taken up. This meeting is conducted with reference to MoEF&CC’s OM vide F. No. 19-21/2020- IA.III (Part) dated 11/03/2020 regarding consideration of proects or activities in respect of Bulk drugs (Active Pharmaceutical Ingredients and Bulk Drug intermediates), out of turn, as a preparedness to the outbreak of Novel Coronavirus (COVID-19). The Committee considered the applications made by project proponents, additional details submitted as required by the SEAC/SEIAA and details furnished in the Form-1, PFR, EIA-EMP reports. Proposal No. Name and Address of the Unit Remarks 1 SIA/GJ/IND2/28859/2019 M/s. Phorvik Pharma Intermediate Appraisal Block Number 452, Village indrad, Tehsil, Kadi, District- Mehsana. Category of the unit: 5(f) Project status: New • Project proponent (PP) has submitted online application vide no. SIA/GJ/IND2/28859/2019 on dated 16/03/2020 for obtaining Environmental Clearance. • The SEAC had recommended TOR to SEIAA and SEIAA issued TOR to PP vide their letter dated 31/12/2018. • Project proponent has submitted EIA Report prepared by M/s. Green Circle Inc, Vadodara based on the TOR issued by SEIAA. • Public Hearing of the Project was conducted by Gujarat Pollution Control Board at Project Site of 613th meeting of SEAC-Gujarat, dated 19.03.2020 Page 1 of 217 M/s. Phorvik Pharma Intermediate, Block Number 452, Village indrad, Tehsil, Kadi, District- Mehsana dated 13/12/2019. • This is new unit proposes for manufacturing of synthetic organic chemical as tabulated below: Sr. Proposed Product Name Cas No. End Use No (MT/Month) 1 Fast Boudreaux G. P. Base 96-96-8 2 Fast Red B Base 97-52-9 45 3 Meta Nitro Para Toluidine 119-32-4 Pharmaceutical 4 2 Nitro 4 Thiocyno Aniline (TCN) 54029-45-7 30 Industries Biss 2 Chloro Ethyl Amine Hydro 5 821-48-7 60 Chloride Dyes and Dyes 6 Fast Scarlet R Base (By Product ) 99-59-2 6.5 Intermediates Total 141.5 • The project falls under Category B of project activity 5(f) as per the schedule of EIA Notification 2006. • The presentation was considred in the meeting dated 18/03/2020 as per the submission by PP via E- mail dated 17/03/2020. • Salient features of the project are as under: Sr. Particulars Details no. Total cost of Proposed Project A Proposed: 3.5 Cr. (Rs. in Crores): ii EMP details (Capital cost & Recurring cost) Capital Total Installed Operating Maintenance Sr. Cost Recurring Unit Capacity Cost Cost No (Rs.in Cost (KLD) (Lacs/Month) (Lacs/Month) Lacs ) (Lacs/Month) Effluent 1 Treatment 14.7 12.0 1.45 0.10 1.55 Plant 2. APCM --- 6.0 0.40 0.10 0.50 TSDF 3 -- 0.50 0.15 - 0.15 Membership Health & 4 -- 0.60 - - - Safety 613th meeting of SEAC-Gujarat, dated 19.03.2020 Page 2 of 217 AWH 5 -- - 0.50 - 0.5 Monitoring Green belt 6 Developmen - 2.9 0.50 - 0.5 t Total 22.0 3.0 0.20 3.2 iii CER details (As per MoEF&CC OM dated 01/05/2018) Year wise Budget (Lakhs) No CER-Proposed Planned Identified 2nd 3rd Area 1st Year . Activities Villages Year Year C R C R C R Promoting education through training and 1. 0. 0. awareness Programme in - - - 0 3 3 consultation with regulatory authority Dhanot, Distribution of notebooks Indrad, 0. 0. 0. 1 Education and school bags and Rajpur, - - - 2 3 3 other required item Chandard Scholarship to bright a students 0. 0. 0. (1th & 2th ) and - - - 5 3 3 appreciation pries to primary teacher Conduct medical camp 0. 0. 0. and distributing first aid Indrad - - - 2 3 3 2 Health boxes in schools Ambavpur General awareness a, Rajpur, 0. 0. 0. - - - health program 3 2 2 Distribution of tree guard Indrad, 0. 0. 0. 0. 0. 0. and pots Bileshvarp 2 5 2 2 2 3 Environmen Training and awareness ura, 3 t Programme in school on Rajpur, 0. 0. 0. - - - Environment day and Indrad, 3 2 2 Safety Day in Ambavpur 613th meeting of SEAC-Gujarat, dated 19.03.2020 Page 3 of 217 consultation with a regulatory authority Indrad Agricultural tour & guide 0. 0. 0. 4 Agriculture Abavpura, - - - to farmers 3 2 2 Dhanot, 3. 0. 2. 0. 2. 0. Total (Year Wise) 0 5 0 2 0 3 7.00 (Capital – 6.0 and Grand Total Recurring – 1.0) Total Plot area B Proposed: 4199 Sq. m. ( sq. meter) Green belt area Proposed: 1385 Sq. m (33%) ( sq. meter) C Employment generation 10 D Water Source of Water Supply Bore well Water Supply (GIDC Bore well, Surface water, Tanker supply etc...) i CGWA Application has been Status of permission from the concern authority. submitted and and requisite processing fees has been paid ii Water consumption (KLD) Sr. Water No Category consumption Remark . in KLD 1 Domestic 1.0 2 Gardening Industrial 4.7 KLD Reuse + 10 Manufacturing process 14.7 3 KLD Fresh Boiler 6.0 Fresh Water Cooling 1.0 Fresh Water Total domestic and gardening 1.0 Total industrial water consumption 21.7 Total Water Requirement 22.7 613th meeting of SEAC-Gujarat, dated 19.03.2020 Page 4 of 217 Reuse Water 4.7 Total Water Requirement after Reuse 18.0 1) Total water requirement for the project: 22.7 KLD 2) Quantity to be recycle: 4.7 KLD 3) Total fresh water requirement: 18.0 KLD iii Waste water generation (KLD) Sr No Category Waste water generation KLD 1 Domestic 0.5 2 Industrial Mfg. Process 14.5 Boiler 0.2 Cooling NIL Total Domestic sewage 0.5 Total Industrial waste water 14.7 Treatment facility within premises with capacity iv [In-house ETP (Primary, Secondary, Tertiary), MEE, Stripper, Spray Dryer, STP etc. Sr No. Description Unit Capacity Collection cum Equalization 1 18 KL 1 Tank 2 Primary Settling 1 5 KL 3 Filter press 1 450 X 450 X 12 Plate 4 Holding tank 1 20 KL Treatment scheme including segregation at source. Collection Send to cum primary Filtter press Holding tank Common Equilization settling Facility tank Note: (In case of CETP discharge) : Management of waste water keeping in view direction under section 18 (1) (b) of the Water (Prevention and Control of Pollution) act, 1974 issued by CPCB regarding compliance of CETP. ➢ Total Waste Water generation 14.7 KLD will be from manufacturing activity and other ancillary operation. These Waste Water will be collected in a tank out of which 4.7 KLD will be reused in the Process. After that the remaining 10 KLD will be sent to Common 613th meeting of SEAC-Gujarat, dated 19.03.2020 Page 5 of 217 Spray Dryer of Chhatral environmental management system for the Evaporation. Brief note on adequacy of ZLD (In case of Zero Liquid Discharge): ➢ Total Waste Water generation 14.7 KLD will be from manufacturing activity and other ancillary operation. These Waste Water will be collected in a tank out of which 4.7 KLD will be reused in the Process. After that the remaining 10 KLD will be sent to Common Spray Dryer of Chhatral environmental management system for the Evaporation. The generated sewage @ 0.5 KLD will be disposed through soak v Domestic: pit/septic tank. Total Waste Water generation 14.7 KLD will be from manufacturing activity and other ancillary operation. These Waste Water will be Industrial: collected in a tank out of which 4.7 KLD will be reused in the Process. After that the remaining 10 KLD will be sent to Common Spray Dryer of Chhatral environmental management system for the Evaporation. In case of Common facility (CF) like CETP, Common Spray dryer, Common MEE, CHWIF etc. Name of Common facility (CF) (For waste water treatment) • Not Applicable vi Membership of Common facility (CF) (For waste water treatment) ➢ Not Applicable. vii Simplified water balance diagram with reuse / recycle of waste water 613th meeting of SEAC-Gujarat, dated 19.03.2020 Page 6 of 217 viii Reuse/Recycle details (4.7 KLD) Total reuse 4.7 KLD Source of waste Application area Remarks water for reuse Characteristics of waste with quantity in regarding with quantity in water to be reused (COD, KLD (Where it is feasibility to KLD (From where it BOD, TDS etc.) used) reuse i.e. is coming) The water will pH – 7 -8 reuse with Manufacturing Manufacturing COD – 90 - 95 fresh water to Process 4.7 KLD Process 4.7 KLD TDS – 1500-1700 dilute the impurities. E Air i Flue gas emission details No. of Boilers/TFH/Furnaces/DG sets etc. with capacities viz. TPH, Kcal/hr, MT/hr, KVA etc. Sr. Stack Stack Consumptio Type of no height in Fuel APCM attached to n Emission . meter 613th meeting of SEAC-Gujarat, dated 19.03.2020 Page 7 of 217 Dust Natural Gas 140 SCM/hr. Boiler Collector and 1 21 OR OR (2 TPH) Multi cyclone Agro Waste 200 Kg/hr PM Separator SOx Thermic Fluid Dust Natural Gas 35 SCM/hr NOx Heater Collector and 2 21 OR OR (3 Lac.
Load more

Recommended publications
  • IJBCP International Journal of Basic & Clinical Pharmacology Antiepileptic
    Print ISSN: 2319-2003 | Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161495 Review Article Antiepileptic drugs: newer targets and new drugs Vihang S. Chawan, Abhishek M. Phatak*, Kalpesh V. Gawand, Sagar V. Badwane, Sagar S. Panchal Department of Pharmacology, TNMC and BYL Nair Ch. Hospital Mumbai, Maharashtra, India ABSTRACT Received: 10 March 2016 Epilepsy is a common neurological disorder affecting 0.5-1% of the population Accepted: 15 April 2016 in India. Majority of patients respond to currently available antiepileptic drugs (AEDs), but a small percentage of patients have shown poor and inadequate *Correspondence to: response to AEDs in addition to various side effects and drug interactions while Dr. Abhishek Madan Phatak, on therapy. Thus there is a need to develop more effective AEDs in drug Email: abhishekphatak9288 resistant epilepsy which have a better safety profile with minimal adverse @gmail.com effects. The United States food and drug administration (USFDA) has approved eslicarbazepine acetate, ezogabine, perampanel and brivaracetam which have Copyright: © the author(s), shown a promising future as better AEDs and drugs like ganaxolone, intranasal publisher and licensee Medip diazepam, ICA- 105665, valnoctamide, VX-765, naluzotan are in the pipeline. Academy. This is an open- access article distributed under Keywords: Epilepsy, Newer antiepileptic drugs, Eslicarbazepine Acetate, the terms of the Creative Ezogabine (Retigabine), Perampanel, Brivaracetam, Naluzotan Commons Attribution Non- Commercial License, which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. INTRODUCTION to AEDs or those patient who have suffered from recurrent seizures, may require surgery.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61K 31/5517 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61P 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/551 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/NL20 14/050781 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 November 2014 (13.1 1.2014) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/903,433 13 November 2013 (13.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Sgc Catalogue 2021.Cdr
    Pharmaceutical Intermediates (Manufacturer & Exporter Since 1999) www.ganeshchemicals.in ABOUT US Shree Ganesh Chemicals is an innovation-driven organization established in 1999. We are working in the eld of pharmaceutical intermediates (API intermediates) & speciality chemicals. We have state of art research, manufacturing, quality testing, and training infrastructure. We are equipped to provide quality pharmaceutical intermediates and custom chemistry services to our customers. Our products are having compliance with various levels of regulatory requirements. The multi disciplinary team of highly qualied technical staff at SGC belongs to various subjects like quality management, technology transfer, and chemistry makes it possible to address different challenges and serve customer's needs better. Our products and services are being successfully used in various countries in Asia, Europe, Africa, and America. VISION VALUES To create chemistr y that can be affordable to human lives and make Sustainability sustainable living Quality Innovation MISSION Teamwork Solving problems to develop chemistry Progress with streamlined solutions Productivity www.ganeshchemicals.in MANUFACTURING FACILITIES From inception in 1999, the company has always concentrated on developing manufacturing infrastructure needed to eciently produce the wide range of pharma chemicals. We are traditionally well placed in - and have continually put in effort & resources to develop our site in Ankleshwar into a state-of-the-art chemical manufacturing site. Today the site in Ankleshwar is over 10,000 sq. mt. of enclosed land - well spaced out production site, common administration, maintenance, utilities, laboratory infrastructure. Our API Intermediates manufacturing facility in Ankleshwar has been conceived and commissioned with the most stringent regulatory requirements in mind and is at par with the best, in terms of machinery specications, water, materials and energy management practices and with regards to Environmental Impact.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Current and Emerging Drug Treatments for Depression in Adults with Epilepsy
    1 CURRENT AND EMERGING DRUG TREATMENTS FOR DEPRESSION IN ADULTS WITH EPILEPSY 1,2 Marco Mula MD PhD and 3,4 Josemir W. Sander MD PhD FRCP 1) Institute of Medical and Biomedical Education, St George’s University of London, UK 2) Atkinson Morley Regional Neuroscience Centre, St George’s University Hospitals NHS Foundation Trust, London, UK 3) NIHR UCL Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square, London WC1N 3BG, & Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, UK 4) Stichting Epilepsie Instellingen Nederland - SEIN, Achterweg 5, Heemstede 2103SW, Netherlands Correspondence to: Prof Ley Sander, Box 29, UCL Institute of Neurology Queen Square, London WC1N 3BG, UK Phone: +44 20 3448 8622; fax: +44 20 3448 8617; e-mail: [email protected] 2 Declaration of interest: MM has received consultancy fees from UCB Pharma, Eisai, Bial and Elsevier and has intellectual property rights with Springer. JWS has received departmental research support from Eisai and UCB Pharma and has been consulted by and received fees for lectures from Bial, Eisai and UCB Pharma outside the submitted work. Acknowledgments: JWS is based at UCLH/UCL Comprehensive Bio-Medical Research Centre, which received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. His current position is endowed by the UK Epilepsy Society and he receives research support from the Dr. Marvin Weil Epilepsy Research Fund. 3 ABSTRACT Introduction: Depression is the most frequent psychiatric comorbidity among people with epilepsy. It can impact on quality of life and increases the risk of morbidity and premature mortality.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Chemical Properties Biological Description Solubility
    Data Sheet (Cat.No.T16265) Naluzotan Chemical Properties CAS No.: 740873-06-7 Formula： C23H38N4O3S Molecular Weight： 450.64 Appearance： N/A Storage： 0-4℃ for short term (days to weeks), or -20℃ for long term (months). Biological Description Description Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiety and depression and is also a weak hERG K+ channel blocker (IC50: 3800 nM). Targets(IC50) 5-HT1A: appr 20 nM In vitro Naluzotan behaves as a full agonist in an in vitro cell-based functional assay (EC50: 20 nM). Naluzotan has obviously affinity is the guinea pig sigma receptor (Ki = 100 nM). However, it does not inhibit cytochrome P450 isoforms (CYP) 1A2, 2C9, 2C19, 2D6, and 3A4[1]. In vivo Naluzotan displays significant brain penetration, achieving a brain: serum concentration ratio of approximately 0.5 in the rat at 1 h following either intravenous or oral administration and reaching brain concentration approximately equivalent to that of buspirone. In rats, Naluzotan (3 mg/kg, p.o.) treatment, displays 11% oral bioavailability with a serum t1/2 of 2−3.5 h when administrated, attaining a Cmax level of 24 ± 13 ng/mL. In dogs, the pharmacokinetic profile of Naluzotan (3 mg/kg, p.o.) treatment, shows 16% oral bioavailability, a serum t1/2 of 1.1 h, and a Cmax level of 174 ± 141 ng/mL [1]. PRX-00023 (0.01-0.05 mg/kg, i.p.) significantly reduces USV rates but done of these doses produce sedation in rats[2].
    [Show full text]